Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine

Nature Medicine

Volumn 20, Issue 6, 2014, Pages 682-688

  Van Allen, Eliezer M ^a,b   Wagle, Nikhil ^a,b   Stojanov, Petar ^a,b   Perrin, Danielle L ^b   Cibulskis, Kristian ^b   Marlow, Sara ^a,b   Jane Valbuena, Judit ^a,b   Friedrich, Dennis C ^b   Kryukov, Gregory ^b   Carter, Scott L ^b   McKenna, Aaron ^b,c   Sivachenko, Andrey ^b   Rosenberg, Mara ^b   Kiezun, Adam ^b   Voet, Douglas ^b   Lawrence, Michael ^b   Lichtenstein, Lee T ^b   Gentry, Jeff G ^b   Huang, Franklin W ^a,b   Fostel, Jennifer ^b   Farlow, Deborah ^b   Barbie, David ^a   Gandhi, Leena ^a   Lander, Eric S ^b   Gray, Stacy W ^a   Joffe, Steven ^a,d   Janne, Pasi ^a   Garber, Judy ^a   Macconaill, Laura ^a,e   Lindeman, Neal ^a,e   Rollins, Barrett ^a   Kantoff, Philip ^a   Fisher, Sheila A ^b   Gabriel, Stacey ^b   Getz, Gad ^a,f   Garraway, Levi A ^a,b   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; DNA; JANUS KINASE 3 INHIBITOR; LY 2835219; NAVELBINE; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER TISSUE; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; COPY NUMBER VARIATION; EXOME; FROZEN SECTION; GENE REARRANGEMENT; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INDEL MUTATION; LUNG ADENOCARCINOMA; METHODOLOGY; MISSENSE MUTATION; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROCESS DESIGN; SOMATIC MUTATION; TISSUE FIXATION; WHOLE EXOME SEQUENCING;

ALGORITHMS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; EXOME; HEK293 CELLS; HUMANS; INDIVIDUALIZED MEDICINE; MASSACHUSETTS; MUTAGENESIS, SITE-DIRECTED; NEOPLASMS; SEQUENCE ANALYSIS, DNA; STATISTICS, NONPARAMETRIC;

EID: 84902148239     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3559     Document Type: Article

References (48)

1. Garraway, L.A. & Lander, E.S. Lessons from the cancer genome. Cell 153, 17-37 (2013).
2. Garraway, L.A. Genomics-driven oncology: framework for an emerging paradigm. J. Clin. Oncol. 31, 1806-1814 (2013).
3. Garraway, L.A. & Janne, P.A. Circumventing cancer drug resistance in the era of personalized medicine. Cancer Discov. 2, 214-226 (2012).
4. Thomas, R.K. et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347-351 (2007). (Pubitemid 46328493)
5. MacConaill, L.E. et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 4, e7887 (2009).
6. Dias-Santagata, D. et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol. Med. 2, 146-158 (2010).
7. Wagle, N. et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2, 82-93 (2012).
8. Lipson, D. et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18, 382-384 (2012).
9. Beltran, H. et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur. Urol. 63, 920-926 (2013).
10. Roychowdhury, S. et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci. Transl. Med. 3, 111ra121 (2011).
11. Craig, D.W. et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol. Cancer Ther. 12, 104-116 (2013).
12. Kerick, M. et al. Targeted high throughput sequencing in clinical cancer settings: formaldehyde fixed-paraffin embedded (FFPE) tumor tissues, input amount and tumor heterogeneity. BMC Med. Genomics 4, 68 (2011).
13. Goetz, L., Bethel, K. & Topol, E.J. Rebooting cancer tissue handling in the sequencing era: toward routine use of frozen tumor tissue. J. Am. Med. Assoc. 309, 37-38 (2013).
14. Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 12, R1 (2011).
15. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
16. Pao, W., Ladanyi, M. & Miller, V.A. Erlotinib in lung cancer. N. Engl. J. Med. 353, 1739-1741 (2005).
17. Williams, C. et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am. J. Pathol. 155, 1467-1471 (1999).
18. Spencer, D.H. et al. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. J. Mol. Diagn. 15, 623-633 (2013).
19. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
20. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
21. Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405-409 (2012).
22. Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251-263 (2012).
23. Barbieri, C.E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012).
24. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011).
25. Lohr, J.G. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. USA 109, 3879-3884 (2012).
26. Cheung, H.W. et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer Discov. 1, 608-625 (2011).
27. Natsume, H. et al. The CRKL gene encoding an adaptor protein is amplified, overexpressed, and a possible therapeutic target in gastric cancer. J. Transl. Med. 10, 97 (2012).
28. Janakiraman, M. et al. Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res. 70, 5901-5911 (2010).
29. Carretero, J. et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17, 547-559 (2010).
30. Forbes, S.A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).
31. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
32. Govindan, R. et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150, 1121-1134 (2012).
33. Puyol, M. et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18, 63-73 (2010).
34. Levine, R.L. JAK-mutant myeloproliferative neoplasms. Curr. Top. Microbiol. Immunol. 355, 119-133 (2012).
35. Boggon, T.J., Li, Y., Manley, P.W. & Eck, M.J. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106, 996-1002 (2005). (Pubitemid 41076445)
36. Malinge, S. et al. Activating mutations in human acute megakaryoblastic leukemia. Blood 112, 4220-4226 (2008).
37. Gonzalez-Angulo, A.M., Hennessy, B.T. & Mills, G.B. Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol. 28, 2777-2783 (2010).
38. Yeh, P. et al. DNA-mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalogue of clinically relevant cancer mutations to enable genome-directed cancer therapy. Clin. Cancer Res. 19, 1894-1901 (2013).
39. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
40. Reich, M. et al. GenePattern 2.0. Nat. Genet. 38, 500-501 (2006).
41. Cibulskis, K. et al. ContEst: estimating cross-contamination of human samples in next-generation sequencing data. Bioinformatics 27, 2601-2602 (2011).
42. Drier, Y. et al. Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res. 23, 228-235 (2013).
43. Chiang, D.Y. et al. High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat. Methods 6, 99-103 (2009).
44. Olshen, A.B., Venkatraman, E.S., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557-572 (2004). (Pubitemid 41180205)
45. Pruitt, K.D., Tatusova, T., Klimke, W. & Maglott, D.R. NCBI reference sequences: current status, policy and new initiatives. Nucleic Acids Res. 37, D32-D36 (2009).
46. Futreal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004). (Pubitemid 38337497)
47. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005). (Pubitemid 41528093)
48. Gehlenborg, N., Noble, M.S., Getz, G., Chin, L. & Park, P.J. Nozzle: a report generation toolkit for data analysis pipelines. Bioinformatics 29, 1089-1091 (2013).